Hi [[ session.user.profile.firstName ]]

pharmaphorum

  • Date
  • Rating
  • Views
  • Engaging with HCPS: what do HCPs want from medical meetings?
    Engaging with HCPS: what do HCPs want from medical meetings? Aoife Delmas, European Society of Cardiology, Katie Koziol and Andrew Moore, Ashfield Meetings & Events Recorded: Jun 26 2018 65 mins
    There has been a myriad of reasons over the past few years to safely assume the popularity and perceived worth of face-to-face medical meetings was well and truly on the decline – from advances in technology, to funding challenges.

    Separate, yet complementary studies looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Yet a 2018 study by Ashfield looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Furthermore, HCPs exhibit consumer behaviours in selecting and attending events – which means that while these conferences offer potential engagement riches, they have to offer a specific mix of focus, value and ROI to be successful. To analyse this situation, discuss the learnings from the research and offer guidance on what a modern medical meeting needs to be we present an exclusive debate.

    Bringing together experts from Ashfield Meetings & Events and the European Society of Cardiology our panel will discuss:

    1. Findings from the 2018 Ashfield Science of HCP Meetings research and whitepaper
    2. How HCPs want to engage with pharma and scientific communications
    3. What works? How to create the events that HCPs want to attend
    4. The future of meetings - balancing face to face and digital
    5. How HCPs determine whether a meeting is likely to be worth the investment
    6. Strategies and tactics for planners and meeting stakeholders to implement to continue to add value for HCPs attending medical meetings
  • How to make digital work in medtech
    How to make digital work in medtech Bryn Davies (Critical Insights), Lars U. Diemer (Agnitio), Markus Ott (Ascensia), Jerome d'Astros (Edwards Lifesciences) Recorded: Jun 21 2018 71 mins
    The rise of mobile devices and apps, not to mention the involvement of non-medical technology players, is creating a wave of irrevocable digital change for medtech.
    It’s transforming how the sector reaches and engages with its stakeholders and customers, and in doing so provides vital opportunities to reshape a company’s commercial model.
    But although the sector can lay claim to some key success stories with digital technology, there remain a number of roadblocks impeding real digital progress for medtech.

    In this webinar we will discuss key digital lessons for medtech from other healthcare sectors, steps to take for a successful digital transformation and how to ensure ROI from digital technology.
    The free webinar will also see our expert panel:
    •Explore the practical impacts of the new medtech business model
    •Re-think the customer experience for payers and HCPs
    •Learn how digital technology enables you to deliver more customer value – while powering commercial success
    •Find out how virtual engagement technologies can make it happen
    •See best practices and use cases from your peers
  • Using education and awareness to drive positive change for patients
    Using education and awareness to drive positive change for patients Gwen Nichols (LLS), Kathleen Weis (AAMDSIF), Brian Tomlinson (CancerCare), Gary Nolan (Know AML), Jenny Kite (Astellas) Recorded: May 3 2018 63 mins
    Change Together will be presenting a live webinar with leading figures from the patient advocacy community, who will debate how we can drive positive change for patients through improved education and awareness. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.
    The panel and the topics they will be covering are as follows.
    • Dr. Gwen Nichols, Chief Medical Officer of the Leukemia & Lymphoma Society on coordinating the group’s groundbreaking Beat AML Master Trial, which is taking the latest research from the lab to the clinic.
    • Kathleen Weis, Chief Executive Officer of the Aplastic Anemia and MDS International Foundation, on the changing treatment landscape, which is bringing new hope to patients, and how her group is supporting the AML community.
    • Representatives from Know AML, the global AML awareness initiative established in 2017 – Gary Nolan from the Know AML secretariat and Brian Tomlinson, patient advocate committee member and Chief Program Officer at CancerCare – explaining how the project started and the role that patient advocates play in it.
  • Digital health: how can technology be used to engage hard-to-reach patients?
    Digital health: how can technology be used to engage hard-to-reach patients? Trishna Bharadia, MS patient advocate, Jo Sopala, MS Trust, Rachel Morrison, NHS Western Isles Recorded: Apr 20 2018 65 mins
    Helping someone live with a condition as complex as MS can be fraught with challenges.

    MS professionals are asked to manage multiple physical and psychological symptoms while following complicated drug monitoring regimes, all in the face of shirking resources and growing caseloads.

    As the burden of monitoring people on disease modifying therapies has grown, a corresponding lack of resource for symptom management has led to inequity of services for those with progressive disease.
    Across the UK, however, technology is being used to overcome these obstacles, by erasing geographic boundaries and expanding access.

    From conducting video consultations to setting up online peer support groups, digital health can and is being utilised to improve services for everyone.

    As part of the Quality in the Delivery of Services (QuDoS) in MS recognition programme, a panel of experts will discuss how to meet the information, support and engagement needs of people living with MS through technology.

    The live webinar, produced by pharmaphorum with the support of the MS Trust and Biogen, will feature the views of patients and professionals alike.

    The panel, which will include Jo Sopala, Director of Development at the MS Trust, will discuss using digital health to:
    -Increase patient access to quality, trusted information through digital translation services
    -Offer greater support through online peer support and symptom management apps
    -Boost adherence through electronic reminder systems
    -Increase involvement in clinical trials through wearable technologies
    -Increase access to services through remote appointments
  • UK pharma and integrated health
    UK pharma and integrated health Stephen Dorrell, NHS Confederation, James Roach, Accountable Care Partnership, Essex Andrew Smith, Cobic, Steve Jowett, IQVIA Recorded: Mar 21 2018 64 mins
    The concept of integrated healthcare is not new to the UK, where it has been discussed since the late 1960s.

    The difference is that now it could really happen. Technology, medicine, regulation and pricing have all evolved to a point where a collaborative, integrated system is not only possible, but desirable – and the data needed for it to become a reality is now available.

    What does this mean for UK pharmaceutical companies that have historically focused on providing medicines and treatments?

    On one hand there are calls for them to change – going beyond being simply a supplier of products and moving into the role of partner, sharing risk to drive great health outcomes.

    On the other hand, the industry’s move into having pipelines that are largely stocked with niche products has created pricing and access questions which are yet to be fully answered.

    Analysing the current situation and looking for potential routes to the future, this high-level IQVIA/pharmaphorum webinar gave an update on the latest developments and debated how pharma can be a catalyst for change at a time when the NHS is under immense pressure to cut costs and become more efficient.

    Insight on these pressing issues was provided by a panel of influential healthcare experts that included former secretary of state for health, and NHS Confederation current chairman, Stephen Dorrell.

    He was joined by:
    James Roach, director, Accountable Care Partnership, West Essex Health and Care System
    Andrew Smith, director, Cobic
    Steve Jowett, country lead for health system engagement, IQVIA

    Watch the digital debate to learn more about:

    The evolving NHS and the STP/ICS model of delivery
    What a collaborative future could look like
    The role of data in the future NHS
    Why the STP/ICS model is important for pharma
  • Driving positive change for patients through collaboration and education
    Driving positive change for patients through collaboration and education Jessica Bateman (UCF); Phyllis Greenberger (HealthyWomen); Steven Gregg (NAFC), Jenny Kite (Astellas US) Recorded: Dec 4 2017 60 mins
    Change Together – www.changetogether.com – will be presenting a live webinar with leading figures from the patient advocacy community, who will debate how we can drive positive change for patients through collaboration and education. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.

    The key topics our expert panel will be covering are:
    – The power of collaboration
    – Educating and communicating with physicians for better patient care
    – Using social media and paid search to extend online engagement and reach
    – Effecting health policy change at a federal and state level
  • Improving commercial decisions with customer relationship network insights
    Improving commercial decisions with customer relationship network insights Megan Oh (Abbott), Leilani Latimer (Zephyr Health), Paul Tunnah (pharmaphorum) Recorded: Nov 28 2017 62 mins
    Networks of influence are shifting the decision-making process for life sciences companies. It is no longer enough to simply view the profile of a HCP or HCO to understand their value to your organization.

    For life sciences organizations, there is currently a gap in information, understanding, and digital access to these critical customer networks and relationships.

    Relying solely on internal knowledge, field experience or purchased data provides an analog, one-dimensional view of these networks. This limits companies from fully understanding key influencers, referral pathways, speaker and authorship networks and more, which once uncovered can significantly influence customer outreach, messaging and engagement.

    In this webinar, we’ll discuss how companies who embrace a holistic data and network analytics approach to strategic planning and execution can achieve significant competitive advantage, improved customer engagement and faster market penetration.
  • The evolution of pharma social media intelligence
    The evolution of pharma social media intelligence Paul Tunnah(Moderator); Professor Andrew Stephen (University of Oxford); Anurag Abinashi (IQVIA) Recorded: Nov 23 2017 61 mins
    Is your company a fully mature user of intelligence from social media, or is it still not tapping into insights?

    As shown in the consumer world, social media can be a very rich source of insights into customers and markets, and can provide early signals of new trends. Exactly the same is true for patient and health care provider insights, especially when used with other more traditional data sets.
    But understanding how to engage, and how to extract the right data to get actionable insights – and all the while complying with regulations – isn’t so straightforward.

    Life sciences companies in particular, want to put this new data source in context with its already broad range of metrics. Achieving this calls for a step-by-step progression towards social media maturity.
    pharmaphorum is working in collaboration with experts from IQVIA and Professor Andrew Stephen of Oxford University to deliver a topical debate focussed on this field, intended to provide answers to some of the conundrums the industry faces.

    An expert panel will provide practical advice and real-life examples of how pharmaceutical companies can develop maturity in social media intelligence.

    Increase your understanding of how social media can easily be used to ultimately add value

    Learn the tricks - how, when and why marketers from other sectors use social media channels to their advantage

    Hear how leading pharma organisations have embraced social media and have seen real results
  • UNLEARN. RELEARN. REIMAGINE. Smarter communications through behavioral science
    UNLEARN. RELEARN. REIMAGINE. Smarter communications through behavioral science Andrew McConaghie, David Hogben (Complete HealthVizion), Robert Poole (Complete HealthVizion), Bjarke Ebert (Lundbeck) Recorded: Nov 22 2017 69 mins
    How can we create smarter, more effective communications for HCPs and patients? What can be done to challenge the status quo, apply a different mindset to communications, and deliver the best possible patient outcomes?

    In this webinar, we will discuss how multichannel strategy and behavioural science are natural partners in creating smarter, more meaningful, and more effective communications. The premise is simple: if we apply a behavioural mindset, we can determine where to focus our communications for the best effect, design the most appropriate multichannel strategy and content, and put the right metrics in place to measure success.
  • Improving outcomes through industry partnership - the Cancer Vanguard learnings
    Improving outcomes through industry partnership - the Cancer Vanguard learnings Paul Tunnah(moderator)Steve Jowett(QuintilesIMS)Rob Duncombe(Christie NHS Foundation Trust)Stuart Hill(Merck)Mike Ringe(ABPI) Recorded: Nov 6 2017 68 mins
    The Cancer Vanguard is a bold initiative setup to take leadership in the delivery of the National Cancer Strategy – Achieving World-Class Cancer Outcomes published in 2015 with a key aim of designing and implementing new and increasingly patient centric models of care in Cancer that can benefit and be adopted by the wider national cancer system.
    In summer 2016 the Cancer Vanguard medicines optimisation team launched the ‘Pharma Challenge’ as an opportunity for the pharma and life sciences industry to identify innovative ways in which it could work in partnership with the NHS to improve the effective use of NHS resources, enhance the NHS’ understanding of the patient experience and make medicines optimisation part of routine practice. Four projects were taken forward including a partnership between the Cancer Vanguard, QuintilesIMS, Merck and uMotif,
    This unique example of partnership working across the health system is focussed on the service at large, not just the pill, and uses leading edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence based and patient centric approach to service redesign and resource optimisation.

Embed in website or blog